Physician profile
Naheed Rizvi
NPI 1992817662
$39,953.88
in general payments reported to CMS, 2019-2025
21 companies · $11K in 2025
The $11K reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $795 · 2020: $171 · 2021: $42.52 · 2022: $79.66 · 2023: $31.36 · 2024: $28K · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $39K · Food and Beverage: $191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $38,675.00 |
| Food and Beverage | $190.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Plasma INC. | $38,675.00 | 2024-2025 | |
| Amgen INC. | $187.01 | 2019 | |
| Abbvie INC. | $186.65 | 2019-2025 | Qulipta |
| Novo Nordisk INC | $164.68 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $153.84 | 2019-2020 | |
| Astellas Pharma US INC | $83.97 | 2019-2024 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.94 | 2019 | |
| Merck Sharp & Dohme LLC | $70.26 | 2019-2020 | |
| Lilly USA, LLC | $52.67 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $41.82 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $41.81 | 2019-2020 | |
| Pfizer INC. | $37.83 | 2019-2020 | |
| Radius Health, INC. | $33.46 | 2019 | |
| Novartis Pharmaceuticals Corporation | $29.07 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $24.00 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $23.65 | 2020 | |
| Medtronic Minimed, INC. | $18.13 | 2019 | |
| Corcept Therapeutics | $16.88 | 2020 | |
| Amag Pharmaceuticals, INC. | $16.25 | 2019 | |
| Dynavax Technologies Corporation | $12.45 | 2022 | |
| Horizon Therapeutics Plc | $11.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naheed Rizvi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.